Salix Pharmaceuticals Ltd (SLXP)

172.81
0.16 0.09
NASDAQ : Health Care
Prev Close 172.65
Open 172.72
Day Low/High 172.71 / 172.96
52 Wk Low/High 86.00 / 172.98
Volume 4.30M
Avg Volume 3.38M
Exchange NASDAQ
Shares Outstanding 64.25M
Market Cap 11.10B
EPS -6.53
P/E Ratio N/A
Div & Yield N.A. (N.A)
Salix Reaches New 52-Week High (SLXP)

Salix Reaches New 52-Week High (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) hit a new 52-week high Monday as it is currently trading at $62.20, above its previous 52-week high of $62.10 with 162,655 shares traded as of 11:51 a.m. ET. Average volume has been 517,700 shares over the past 30 days.

Salix Stock Hits New 52-Week High (SLXP)

Salix Stock Hits New 52-Week High (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) hit a new 52-week high Friday as it is currently trading at $62.01, above its previous 52-week high of $61.92 with 119,901 shares traded as of 12:55 p.m. ET. Average volume has been 524,600 shares over the past 30 days.

Salix Stock Hits New 52-Week High (SLXP)

Salix Stock Hits New 52-Week High (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) hit a new 52-week high Friday as it is currently trading at $60.35, above its previous 52-week high of $60.20 with 250,292 shares traded as of 12:20 p.m. ET. Average volume has been 528,200 shares over the past 30 days.

Salix Stock Hits New 52-Week High (SLXP)

Salix Stock Hits New 52-Week High (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) hit a new 52-week high Wednesday as it is currently trading at $59.65, above its previous 52-week high of $59.46 with 8,551 shares traded as of 9:31 a.m. ET. Average volume has been 520,900 shares over the past 30 days.

Salix Pharmaceuticals Reports 4Q2012 And FY2012 Results

Salix Pharmaceuticals Reports 4Q2012 And FY2012 Results

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the fourth quarter and full year ended December 31, 2012 and other business updates.

Salix Pharmaceuticals To Present At Two Investment Conferences In March

Salix Pharmaceuticals To Present At Two Investment Conferences In March

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at two investment conferences during March 2013.

Salix Pharmaceuticals Announces 4Q2012 And FY2012 Financial Results Conference Call And Webcast

Salix Pharmaceuticals Announces 4Q2012 And FY2012 Financial Results Conference Call And Webcast

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report fourth quarter and full year 2012 financial results following the close of the U.

Salix Pharmaceuticals Ltd. Stock Upgraded (SLXP)

Salix Pharmaceuticals Ltd. Stock Upgraded (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) has been upgraded by TheStreet Ratings from a hold to buy.

FDA Approves Fulyzaq™ (Crofelemer) 125 Mg Delayed-Release Tablets For The Symptomatic Relief Of Diarrhea In Patients With HIV/AIDS On Anti-Retroviral Therapy (ART)

FDA Approves Fulyzaq™ (Crofelemer) 125 Mg Delayed-Release Tablets For The Symptomatic Relief Of Diarrhea In Patients With HIV/AIDS On Anti-Retroviral Therapy (ART)

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Food and Drug Administration has approved Fulyzaq™ (crofelemer) 125 mg delayed-release tablets for the symptomatic relief of non-infectious ...

Salix Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Salix Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at The 31 st Annual J.

FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs

FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs

Drugs from Salix Pharma, Nektar Therapeutics and Cubist Pharma may be forced into long delays by FDA's request for heart-safety data.

Salix Pharmaceuticals Previews The American Association For The Study Of Liver Diseases 2012

Salix Pharmaceuticals Previews The American Association For The Study Of Liver Diseases 2012

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that educational activities and numerous presentations describing the investigation of XIFAXAN ® 550mg/rifaximin will occur during The 63 rd Annual Meeting...

Salix Pharmaceuticals Ltd. Stock Downgraded (SLXP)

Salix Pharmaceuticals Ltd. Stock Downgraded (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) has been downgraded by TheStreet Ratings from from a buy to hold.

Salix Pharmaceuticals Reports 3Q2012 Results

Salix Pharmaceuticals Reports 3Q2012 Results

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the third quarter ended September 30, 2012 and other business updates.

Salix Pharmaceuticals To Present At Two Investment Conferences In November

Salix Pharmaceuticals To Present At Two Investment Conferences In November

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at two investment conferences during November 2012.

Salix Pharmaceuticals Announces 3Q2012 Financial Results Conference Call And Webcast

Salix Pharmaceuticals Announces 3Q2012 Financial Results Conference Call And Webcast

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report third quarter 2012 financial results following the close of the U.

New Documentary, “Wrestling The Monster: Living With Hepatic Encephalopathy,” Premieres At American College Of Gastroenterology 2012 Scientific Meeting

New Documentary, “Wrestling The Monster: Living With Hepatic Encephalopathy,” Premieres At American College Of Gastroenterology 2012 Scientific Meeting

Today Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced the premiere screening of “ Wrestling the Monster: Living with Hepatic Encephalopathy” at the 2012 American College of Gastroenterology...

Salix Pharmaceuticals Previews American College Of Gastroenterology 2012

Salix Pharmaceuticals Previews American College Of Gastroenterology 2012

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that educational activities and numerous presentations describing the investigation of several of the Company’s products – including XIFAXAN ® ...

Nektar Therapeutics Is a Short

Nektar Therapeutics Is a Short

Investor Martin Shkreli believes Nektar's constipation drug is a bust and the stock is a good short.

Salix Pharmaceuticals Outlines Data Presentations At PAINWeek

Salix Pharmaceuticals Outlines Data Presentations At PAINWeek

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that five presentations describing the investigation of methylnaltrexone bromide as a potential treatment for opioid-induced constipation in adult patients with...

FDA Continues Review Of Crofelemer New Drug Application Beyond PDUFA Goal Date Of September 5, 2012

FDA Continues Review Of Crofelemer New Drug Application Beyond PDUFA Goal Date Of September 5, 2012

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Food and Drug Administration has advised the Company that its New Drug Application (NDA) for crofelemer 125 mg tablets, for the proposed indication of...

Salix Pharmaceuticals Ltd. (SLXP): Today's Featured Health Care Laggard

Salix Pharmaceuticals Ltd. (SLXP): Today's Featured Health Care Laggard

Salix Pharmaceuticals was a leading decliner within the health care sector, falling 68 cents (-1.5%) to $44.22 on light volume.

Salix Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Salix Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Salix Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Salix Pharmaceuticals And Alfa Wassermann Announce License Agreement For A New Extended Intestinal Release Formulation Of Rifaximin

Salix Pharmaceuticals And Alfa Wassermann Announce License Agreement For A New Extended Intestinal Release Formulation Of Rifaximin

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Alfa Wassermann S.

Salix Pharmaceuticals Reports 2Q2012 Results

Salix Pharmaceuticals Reports 2Q2012 Results

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the second quarter ended June 30, 2012 and other business updates.

7 Most Reliable Growth Stocks in the Market

7 Most Reliable Growth Stocks in the Market

Here are seven companies that are poised for strong growth ahead, according to the analysts that track them.

Stocks Take Breather After Recent Surge

Stocks Take Breather After Recent Surge

The Dow snaps a three-day winning streak amid some mild profit-taking ahead of the Fed's policy meeting this week.

Salix And Progenics Receive Complete Response Letter From FDA For RELISTOR® SNDA

Salix And Progenics Receive Complete Response Letter From FDA For RELISTOR® SNDA

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals (NASDAQ:PGNX) today received at approximately 5:00 p.

Salix Pharmaceuticals Announces 2Q2012 Financial Results Conference Call And Webcast

Salix Pharmaceuticals Announces 2Q2012 Financial Results Conference Call And Webcast

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report second quarter 2012 financial results following the close of the U.

Salix Stock Hits New 52-Week High (SLXP)

Salix Stock Hits New 52-Week High (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) hit a new 52-week high Monday as it is currently trading at $54.66, above its previous 52-week high of $54.57 with 17,567 shares traded as of 9:35 a.m. ET. Average volume has been 878,900 shares over the past 30 days.